Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K5 | Q99683 | 18/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | ESR1 | P03372 | 1/20 | 0.37 |
| ▸ | AKT1 | P31749 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15811799 | 0.89 | MAP3K5 (0.45) | MAP3K5KDM4EALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL30433332 | 0.89 | MAP3K5 (0.45) | MAP3K5KDM4EALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL21461179 | 0.87 | MAP3K5 (0.45) | MAP3K5KDM4EALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL20557512 | 0.86 | MAP3K5 (0.47) | MAP3K5KDM4EALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL30433017 | 0.86 | MAP3K5 (0.47) | MAP3K5KDM4EALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL21461018 | 0.84 | MAP3K5 (0.49) | MAP3K5AKT1 | |
| SCHEMBL21461037 | 0.84 | MAP3K5 (0.49) | MAP3K5AKT1 | |
| SCHEMBL31249002 | 0.83 | MAP3K5 (0.49) | MAP3K5AKT1 | |
| SCHEMBL31249019 | 0.83 | MAP3K5 (0.49) | MAP3K5AKT1 | |
| SCHEMBL17880577 | 0.82 | MAP3K5 (0.55) | MAP3K5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230174515-A1 | APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS AND METHODS OF USE THEREOF | ENANTA PHARM INC (US) | 2023-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230174515-A1 | APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS AND METHODS OF USE THEREOF | BAD, CASP1, BAX | MAP3K5 23/4885KDM4E 2139/4885ALDH1A1 1882/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.